| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MBD2 |
| Uniprot No | Q9UBB5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 143-411aa |
| 氨基酸序列 | ATESGKRMDCPALPPGWKKEEVIRKSGLSAGKSDVYYFSPSGKKFRSKPQLARYLGNTVDLSSFDFRTGKMMPSKLQKNKQRLRNDPLNQNKGKPDLNTTLPIRQTASIFKQPVTKVTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGLSASDVTEQIIKTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAVWLNTSQPLCKAFIVTDEDIRKQEERVQQVRKKLEEALMADILSRAADTEEMDIEMDSGDEA |
| 预测分子量 | 45.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MBD2重组蛋白的模拟参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**：Purification and functional analysis of recombinant MBD2 protein in DNA methylation recognition
**作者**：Smith A, et al.
**摘要**：本研究描述了通过原核表达系统高效表达并纯化MBD2重组蛋白，验证其特异性结合甲基化DNA的能力，并揭示其在体外调控基因沉默的分子机制。
2. **文献名称**：Structural characterization of MBD2 recombinant protein and its interaction with NuRD complex
**作者**：Zhang Y, et al.
**摘要**：利用X射线晶体学解析MBD2重组蛋白结构，结合免疫共沉淀实验证实其与NuRD复合物的相互作用，为表观遗传调控网络提供结构生物学证据。
3. **文献名称**：Development of a MBD2-based recombinant protein for epigenetic biomarker detection
**作者**：Tanaka K, et al.
**摘要**：构建携带His标签的MBD2重组蛋白，开发基于ELISA的甲基化DNA检测技术，展示其在癌症早期诊断中的应用潜力。
4. **文献名称**：Comparative study of MBD2 isoforms: Expression optimization and methylation binding specificity
**作者**：Gupta R, et al.
**摘要**：系统比较MBD2两种剪切异构体的重组表达条件差异，通过凝胶迁移实验揭示两者在CpG甲基化模式识别中的不同偏好性。
注：以上文献信息均为模拟生成，实际文献请通过PubMed、Web of Science等学术平台查询。
MBD2 (Methyl-CpG-binding domain protein 2) is a key epigenetic regulator belonging to the methyl-CpG-binding domain (MBD) protein family, which recognizes and binds to methylated DNA regions. It plays a critical role in mediating gene silencing by recruiting chromatin-modifying complexes, such as the NuRD (Nucleosome Remodeling and Deacetylase) complex, to methylated CpG islands. This process facilitates histone deacetylation, chromatin compaction, and transcriptional repression, influencing cellular processes like development, differentiation, and tumor suppression. Dysregulation of MBD2 is linked to cancers, neurological disorders, and immune diseases, making it a target for therapeutic research.
Recombinant MBD2 proteins are engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional versions of the protein for experimental studies. These proteins often include affinity tags (e.g., GST, His-tag) for simplified purification and detection. Researchers utilize recombinant MBD2 to investigate DNA methylation-dependent gene regulation, protein-DNA/protein interactions, and mechanisms of epigenetic inheritance. It also serves as a tool for screening small-molecule inhibitors targeting MBD2’s methyl-binding activity or its role in disease-associated pathways. Additionally, its applications extend to diagnostic assays detecting aberrant DNA methylation patterns in cancer or developmental disorders. By enabling precise manipulation of epigenetic processes, recombinant MBD2 advances both basic research and translational studies in epigenetics.
×
